FDA approves single-vial version of GSK's Menveo vaccine, ending need for reconstitution

GSK has won FDA approval for a single-vial formulation of its meningococcal disease vaccine Menveo, thereby ending the need for reconstitution that has existed since the product came to market in 2010.